Key considerations in microbiome partnering

March 29, 2017 Christoph Graener

 

The human microbiome is garnering research interest across the globe and industry is responding to the growing possibilities of therapeutic developments in a variety of ways, a key aspect of which is partnerships. The current state of play means emerging companies are often looking for specific expertise or experience in their partners, often influenced by the variety of approaches under different regulatory jurisdictions or financial structures.


Moderator: Mike Ward – Informa Pharma Insights

  • Xavier Aldeguer Mauté – Goodgut
  • Michel de Baar – MSD
  • Eric de la Fortelle – Seventure
  • Mariona Serra-Pagès – Goodgut

 

Previous Article
Making early investment decisions: Incorporating flexibility into your R&D strategy

Strategic decisions made early in clinical development often have an impact on the downstream commercial po...

Next Article
Dimerix CEO explains company’s different drug combo R&D strategy
Dimerix CEO explains company’s different drug combo R&D strategy

Kathy Harrison, CEO of Australian biotech Dimerix, talks about the company's unusual business model, Dimeri...